# Anticoagulation Using Rivaroxaban on Top of Aspirin in Intracranial Atherosclerotic Stenosis

Study · id `cardio:ct-nct05700266` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05700266](<https://clinicaltrials.gov/study/NCT05700266>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05700266

Browse, organ or system: Brain  
Browse, condition area: Stroke  

## In plain language

A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 1180 participants.

## Technical summary

Registry record NCT05700266. Randomized; single masking; primary purpose prevention. Start 2023-12-30 (anticipated); primary completion 2024-12 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose prevention
- Phase: Phase 2/3
- Enrolled: 1180 participants (planned count; ClinicalTrials.gov record NCT05700266, source copy `cardio:ctgov-nct05700266-2023-12-21`, retrieved 2026-10-26)
- Planned start: 2023-12-30 (anticipated) (ClinicalTrials.gov record NCT05700266, source copy `cardio:ctgov-nct05700266-2023-12-21`, retrieved 2026-10-26)
- Primary completion: 2024-12 (anticipated) (ClinicalTrials.gov record NCT05700266, source copy `cardio:ctgov-nct05700266-2023-12-21`, retrieved 2026-10-26)
- Completion: 2024-12 (anticipated) (ClinicalTrials.gov record NCT05700266, source copy `cardio:ctgov-nct05700266-2023-12-21`, retrieved 2026-10-26)
- Countries: Not reported
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05700266-2023-12-21`, retrieved 2026-10-26)

## The registry's words

- Brief title: Anticoagulation Using Rivaroxaban on Top of Aspirin in Intracranial Atherosclerotic Stenosis
- Acronym: AA-ICAS
- Condition: Ischemic Stroke
- Condition: Intracranial Atherosclerosis
- Condition: Stenosis
- Intervention (Drug): Rivaroxaban
- Intervention (Drug): Clopidogrel
- Intervention (Drug): Aspirin
- Intervention (Other): Risk Factor Management in both arms
- Lead sponsor: The First Affiliated Hospital with Nanjing Medical University
- Lead sponsor class: OTHER
- Collaborator: National Natural Science Foundation of China
- Collaborator class: OTHER\_GOV

## Connected pages

- Registry condition terms include this condition: Ischemic stroke (`cardio:ischemic-stroke`)
- Registry condition terms include this condition: Stroke (`core:stroke`)
- Registry intervention name matches this record: Rivaroxaban (`cardio:rivaroxaban`)
- Registry intervention name matches this record: Clopidogrel (`cardio:clopidogrel`)
- Registry intervention name matches this record: Aspirin (`core:aspirin`)
- Registry lists this organization as the lead sponsor: The First Affiliated Hospital with Nanjing Medical University (`cardio:org-the-first-affiliated-hospital-with-nanjing-medical-898271`)
- Registry lists this organization as a collaborator: National Natural Science Foundation of China (`cardio:org-national-natural-science-foundation-of-china`)

## Provenance

Content hash: 4ace47aee213b24a569768960638c689f47d21e24cbc79813b7ffbb39508d1e4
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
